Preventing invasive meningococcal disease in early infancy

Hum Vaccin Immunother. 2022 Nov 30;18(5):1979846. doi: 10.1080/21645515.2021.1979846. Epub 2022 Apr 28.

Abstract

This review considers the pathogenesis, diagnosis, and epidemiology of invasive meningococcal disease in infants, to examine and critique meningococcal disease prevention in this population through vaccination. High rates of meningococcal disease and poor outcomes, particularly for very young infants, highlight the importance of meningococcal vaccination in early infancy. Although effective and safe meningococcal vaccines are available for use from 6 weeks of age, they are not recommended globally. Emerging real-world data from the increased incorporation of these vaccines within immunization programs inform recommendations regarding effectiveness, appropriate vaccination schedule, possible long-term safety effects, and persistence of antibody responses. Importantly, to protect infants from IMD, national vaccination recommendations should be consistent with available data regarding vaccine safety, effectiveness, and disease risk.

Keywords: Infant; maternal vaccination; meningococcal; passive immunity; vaccination.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunization Schedule
  • Infant
  • Meningococcal Infections* / epidemiology
  • Meningococcal Infections* / prevention & control
  • Meningococcal Vaccines* / therapeutic use
  • Neisseria meningitidis*
  • Vaccination

Substances

  • Meningococcal Vaccines

Grants and funding

This work was sponsored by Pfizer Inc.